aplaviroc Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Aplaviroc is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines developed for the treatment of HIV infection. It was developed by GlaxoSmithKline.   Wikipedia

Chemistry

  • SMILES: CCCCN1C(=O)[C@H](NC(=O)C12CCN(Cc3ccc(Oc4ccc(cc4)C(=O)O)cc3)CC2)[C@H](O)C5CCCCC5
  • InChIKey: GWNOTCOIYUNTQP-FQLXRVMXSA-N
  • Mol. Mass: 577.72
  • ALogP: 4.58
  • ChEMBL Molecules:
    aplaviroc  
    aplaviroc hydrochloride  
More Chemistry

Pharmacology

Alternative names

4-((4-(((3r)-1-butyl-3-((r)-cyclohexyl(hydroxy)methyl)-2,5-dioxo-1,4,9-triazaspiro(5.5)undec-9-yl)methyl)phenyl)oxy)benzoic acid hydrochloride | aplaviroc | aplaviroc hcl | aplaviroc hydrochloride | benzoic acid, 4-(4-(((3r)-1-butyl-3-((r)-cyclohexylhydroxymethyl)-2,5-dioxo-1,4,9- triazaspiro(55)undec-9-yl)methyl)phenoxy)- | gw873140 | gw873140a

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

HIV (Phase 3)

HIV Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue